Ribociclib Hydrochloride is a selective kinase inhibitor classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast… Read more
Ribociclib Hydrochloride is a selective kinase inhibitor classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. This category contains a range of essential reference standards, including the active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled compounds. These high-quality materials are critical tools for pharmaceutical laboratories and research facilities, supporting rigorous analytical testing, method validation, and quality control processes. By utilizing these precise standards, analysts can perform accurate impurity profiling, stability testing, and forced degradation studies, ensuring that drug formulations meet necessary safety and regulatory requirements. These compounds are vital for confirming the structural integrity and purity of the drug substance throughout its development, formulation, and manufacturing lifecycle.